Herceptin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Herceptin Market was valued at USD 3.51 Billion in 2024, and is expected to reach USD 4.92 Billion by 2030, rising at a CAGR of 5.77%. This market is witnessing steady growth driven by the rising incidence of HER2-positive breast and gastric cancers. Herceptin (trastuzumab), a monoclonal antibody, has established itself as a foundational therapy in HER2-targeted treatment strategies.

Increasing adoption of precision medicine, improvements in HER2 diagnostic testing, and integration of trastuzumab into clinical protocols for both early and metastatic stages of cancer are supporting market expansion. Enhanced survival outcomes and robust clinical backing continue to strengthen demand. Growth is further reinforced by advancements in diagnostic tools, rising healthcare investments, and the uptake of subcutaneous formulations that improve treatment convenience. The expanding biosimilar landscape is also broadening access, supporting global market growth while intensifying competition and driving innovation in delivery formats and combination therapies.

Key Market Drivers

Increasing Prevalence of HER2-Positive Cancers

The escalating incidence of HER2-positive breast and gastric cancers is significantly boosting demand for Herceptin. HER2 overexpression, identified in a notable subset of patients, enables targeted therapy using trastuzumab. As breast cancer remains the most diagnosed cancer globally, the population eligible for HER2-directed treatments continues to rise. In the U.S., HER2-positive subtypes account for nearly 13.6% of female breast cancer cases, and the burden is similarly high in certain gastric and gastroesophageal cancers, particularly in East Asia and Eastern Europe. The rising need for precise and effective therapies has reinforced Herceptin’s clinical value, making it a critical part of standard treatment regimens in oncology.

Key Market Challenges

Patent Expiry and Growing Biosimilar Competition

The expiration of Herceptin’s patent protection has opened the market to numerous biosimilars, reshaping competitive dynamics. Regions like the U.S. and Europe have seen an influx of biosimilar alternatives, driving down prices and reducing the market share of the originator product. Healthcare systems, under pressure to optimize costs, are increasingly favoring biosimilars in treatment guidelines and procurement policies. This has intensified pricing pressure and limited brand differentiation. Manufacturers of Herceptin are responding through lifecycle management initiatives, including patient access programs and a strategic pivot toward newer combination therapies. However, sustaining profitability and market share amid widespread biosimilar adoption remains a significant challenge.

Key Market Trends

Shift Toward Combination and Sequential Therapies

The Herceptin market is evolving with a growing emphasis on combination and sequential treatment approaches. Clinicians are increasingly combining trastuzumab with chemotherapies, other biologics, and antibody-drug conjugates to improve outcomes in HER2-positive cancers. The incorporation of pertuzumab and docetaxel alongside trastuzumab, as well as the growing use of antibody-drug conjugates like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan, reflect this shift. These regimens have demonstrated superior efficacy in both metastatic and adjuvant settings. Sequential therapy - transitioning from trastuzumab to ADCs or TKIs - is also being adopted in cases of disease progression, extending Herceptin’s role across multiple lines of treatment.

Key Market Players

• Roche Holding AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Amgen Inc.
• Celltrion Healthcare Co., Ltd.
• Biocon Limited
• Mylan N.V. (Viatris)
• Prestige Biopharma
• Shanghai Henlius Biotech, Inc.
• Dr. Reddy’s Laboratories

Report Scope:

In this report, the Global Herceptin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Herceptin Market, By Product:

• Biologic
• Biosimilar

Herceptin Market, By Application:

• Breast Cancer
• Stomach/Gastric Cancer
• Others

Herceptin Market, By Distribution Channel:

• Hospital Pharmacy
• Specialty Pharmacy
• Others

Herceptin Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herceptin Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.